Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans.
BACKGROUND
There is increasing evidence that immune processes are important in the development of atherosclerosis. We investigated whether low density lipoprotein (LDL) adsorption therapy affected serum cytokine levels and the expression of adhesion molecules on peripheral blood mononuclear cells (lymphocytes and monocytes) in patients with arteriosclerotic obliterance (ASO).


RESULTS
LDL adsorption therapy was repeated ten times over a period of three months in ten ASO patients. The total serum cholesterol and LDL cholesterol levels were significantly reduced at the end of therapy. This was associated with a significant improvement in Fontaine's classification and ankle pressure index. We also measured serum levels of inflammatory cytokines (interleukin-1 beta (IL-1 beta), IL-6 and tissue necrosis factor alpha (TNF-alpha)) and expression of adhesion molecules (lymphocyte function-associated antigen 1 alpha (LFA-1 alpha), LFA-1 beta, CD2, very late antigen (VLA)-4, VLA-5 and CD44) on mononuclear cells in the same patients and a group of healthy subjects. Serum levels of all inflammatory cytokines were markedly higher in ASO patients compared with healthy subjects, but there was no significant difference in the level before and after LDL adsorption. VLA-4 expression on CD3+ cells, but not of other adhesion molecules, was markedly higher in ASO patients compared with healthy subjects. LDL adsorption caused a significant reduction in CD2, VLA4 and VLA-5 expression on CD3+ cells. Furthermore, VLA-4 and VLA-5 expression on monocytes diminished significantly after LDL adsorption.


CONCLUSIONS
Our results indicate that LDL adsorption-induced immunoregulation is mediated by an indirect stimulatory effect on the immune system. The results suggests that improved peripheral circulation produced by LDL adsorption may reflect improved immune dysfunctions of atherosclerotic lesions in ASO patients.
D000368:Aged; D000369:Aged, 80 and over; D001162:Arteriosclerosis Obliterans / Q000097:blood / Q000150:complications / Q000276:immunology* / Q000628:therapy; D017252:CD3 Complex / Q000032:analysis; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D016207:Cytokines / Q000097:blood; D005260:Female; D006464:Hemoperfusion; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000097:blood*; D016131:Lymphocyte Subsets / Q000378:metabolism; D008297:Male; D012720:Severity of Illness Index
D017252:CD3 Complex; D015815:Cell Adhesion Molecules; D016207:Cytokines; D008077:Lipoproteins, LDL